BRAF and melanoma: The discovery of the BRAFV600E substitution as the most common genetic event in melanoma [1] rapidly led to the clinical development of selective ATP-competitive RAF kinase inhibitors (i.e. Vemurafenib, Dabrafenib) targeting the mutant BRAF protein [2, 3].